Merlin Capital LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Merlin Capital LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Merlin Capital LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 7.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,813 shares of the pharmaceutical company's stock after selling 221 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 1.6% of Merlin Capital LLC's investment portfolio, making the stock its 15th biggest position. Merlin Capital LLC's holdings in Vertex Pharmaceuticals were worth $793,000 as of its most recent SEC filing.
據HoldingsChannel.com報道,梅林資本有限責任公司在第二季度減持了Vertex製藥公司的股票(納斯達克代碼:VRTX-GET評級)7.3%。該公司在本季度出售了221股後,擁有2,813股輝瑞股票。Vertex PharmPharmticals在Merlin Capital LLC的投資組合中約佔1.6%,使該股成為其第15大頭寸。截至最近提交給美國證券交易委員會的文件,梅林資本持有的Vertex PharmPharmticals股份價值793,000美元。
Several other institutional investors have also added to or reduced their stakes in VRTX. Norges Bank purchased a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $588,506,000. Wellington Management Group LLP lifted its holdings in shares of Vertex Pharmaceuticals by 23.6% during the 1st quarter. Wellington Management Group LLP now owns 8,053,710 shares of the pharmaceutical company's stock valued at $2,101,776,000 after buying an additional 1,535,255 shares during the period. Capital World Investors lifted its holdings in shares of Vertex Pharmaceuticals by 9.9% during the 1st quarter. Capital World Investors now owns 12,666,130 shares of the pharmaceutical company's stock valued at $3,305,417,000 after buying an additional 1,145,275 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at $167,910,000. Finally, Aaron Wealth Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 25,712.2% during the 1st quarter. Aaron Wealth Advisors LLC now owns 591,358 shares of the pharmaceutical company's stock valued at $2,266,000 after buying an additional 589,067 shares during the period. 91.33% of the stock is currently owned by hedge funds and other institutional investors.
其他幾家機構投資者也增持或減持了VRTX的股份。挪威銀行在第四季度購買了Vertex PharmPharmticals的新股份,價值588,506,000美元。惠靈頓管理集團(Wellington Management Group LLP)第一季度增持Vertex PharmPharmticals股票23.6%。惠靈頓管理集團現在擁有8,053,710股這家制藥公司的股票,價值2,101,776,000美元,在此期間又購買了1,535,255股。Capital World Investors在第一季度增持了Vertex PharmPharmticals的股票9.9%。Capital World Investors現在持有這家制藥公司12,666,130股股票,價值3,305,417,000美元,在此期間又購買了1,145,275股。阿貝特勛爵公司。LLC在第一季度購買了Vertex PharmPharmticals的新頭寸,價值167,910,000美元。最後,Aaron Wealth Advisors LLC在第一季度增持了25,712.2%的Vertex PharmPharmticals股票。Aaron Wealth Advisors LLC現在擁有591,358股這家制藥公司的股票,價值2,266,000美元,在此期間又購買了589,067股。91.33%的股票目前由對衝基金和其他機構投資者持有。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
VRTX has been the topic of a number of recent research reports. Maxim Group raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and set a $325.00 target price on the stock in a report on Wednesday, June 1st. Cantor Fitzgerald initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, July 12th. They issued an "overweight" rating and a $365.00 target price on the stock. HC Wainwright raised their target price on Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a report on Friday, August 5th. Barclays raised their target price on Vertex Pharmaceuticals from $291.00 to $307.00 and gave the stock an "overweight" rating in a report on Friday, August 5th. Finally, Piper Sandler raised their target price on Vertex Pharmaceuticals from $256.00 to $288.00 and gave the stock a "neutral" rating in a report on Tuesday, August 16th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $291.65.
VRTX是最近一些研究報告的主題。Maxim Group在6月1日週三的一份報告中將Vertex PharmPharmticals的評級從持有上調至買入,併為該股設定了325.00美元的目標價。坎託·菲茨傑拉德在7月12日星期二的一份報告中發起了對Vertex製藥的報道。他們對該股的評級為“增持”,目標價為365.00美元。在週五的一份報告中,HC Wainwright將Vertex PharmPharmticals的目標價從275.00美元上調至300.00美元,並給予該股“買入”評級。巴克萊在週五的一份報告中將Vertex PharmPharmticals的目標價從291.00美元上調至307.00美元,並給予該股“增持”評級。最後,派珀·桑德勒在8月16日(週二)的一份報告中將Vertex PharmPharmticals的目標價從256.00美元上調至288.00美元,並給予該股“中性”評級。6名投資分析師對該股的評級為持有,11名分析師給出了買入評級,一名分析師給出了該公司股票的強力買入評級。根據MarketBeat的數據,Vertex PharmPharmticals目前的共識評級為“中等買入”,共識目標價為291.65美元。
Insider Buying and Selling at Vertex Pharmaceuticals
Vertex PharmPharmticals的內幕買賣
Vertex Pharmaceuticals Trading Up 2.6 %
Vertex製藥公司股價上漲2.6%
VRTX traded up $7.49 on Wednesday, hitting $292.23. The company had a trading volume of 49,445 shares, compared to its average volume of 1,267,073. The company has a market cap of $74.95 billion, a PE ratio of 23.52, a PEG ratio of 1.97 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a 12-month low of $176.36 and a 12-month high of $305.95. The company has a quick ratio of 4.36, a current ratio of 4.50 and a debt-to-equity ratio of 0.04. The business's fifty day simple moving average is $286.74 and its 200 day simple moving average is $274.82.
週三,VRTX股價上漲7.49美元,至292.23美元。該公司的成交量為49,445股,而其平均成交量為1,267,073股。該公司市值為749.5億美元,市盈率為23.52倍,聚乙二醇率為1.97倍,貝塔係數為0.45。Vertex PharmPharmticals Inc.的12個月低點為176.36美元,12個月高位為305.95美元。該公司的速動比率為4.36,流動比率為4.50,債務權益比率為0.04。該業務的50日簡單移動均線切入位為286.74美元,200日簡單移動均線切入位為274.82美元。
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The pharmaceutical company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.05 by $0.20. The company had revenue of $2.20 billion during the quarter, compared to analyst estimates of $2.13 billion. Vertex Pharmaceuticals had a return on equity of 31.22% and a net margin of 38.26%. The firm's revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $2.80 earnings per share. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.56 EPS for the current year.
頂點製藥(納斯達克:VRTX-GET評級)最近一次發佈季度收益報告是在8月4日(星期四)。這家制藥公司公佈本季度每股收益為3.25美元,比普遍預期的3.05美元高出0.20美元。該公司本季度營收為22.億美元,而分析師預期為21.3億美元。Vertex製藥的股本回報率為31.22%,淨利潤率為38.26%。該公司的收入同比增長了22.5%。去年同一季度,該公司公佈的每股收益為2.80美元。股票研究分析師預計,Vertex製藥公司本年度每股收益將達到12.56股。
Vertex Pharmaceuticals Profile
Vertex PharmPharmticals簡介
(Get Rating)
(獲取評級)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
Vertex製藥公司是一家生物技術公司,致力於開發治療囊性纖維化的療法並將其商業化。該公司銷售SYMDEKO/SYMKEVI、Orkambi和Kalydeco,用於治療囊性纖維化患者,這些患者的囊性纖維化跨膜傳導調節基因具有特定突變;TRIKAFTA用於治療至少有一種F508del突變的6歲或6歲以上的CF患者。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- 免費獲取StockNews.com關於Vertex PharmPharmticals的研究報告(VRTX)
- 聯合天然食品能同時對抗通脹和美聯儲嗎?
- 馬倫汽車已做好準備投入使用
- 餅乾桶:可口的款待還是壞蘋果?
- 防禦性股票應對動盪的市場
- SunPower準備推動三位數的收益增長
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating).
想看看還有哪些對衝基金持有VRTX嗎?訪問HoldingsChannel.com獲取Vertex PharmPharmticals Inc.(納斯達克代碼:VRTX-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vertex製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vertex製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。